Chimeric antigen receptor (CAR) T cell therapy has limited efficacy in treating solid tumors, and new approaches are needed to improve patient outcomes. As a strategy to improve the therapeutic success of CAR T cells directed against solid tumors, Dr. Uslu and his colleagues at the Center for Cellular Immunotherapies, University of Pennsylvania, tested the combinatorial use of CAR T cells and IMSA101—a newly developed stimulator of interferon genes (STING) agonist. In two syngeneic tumor models, improved overall survival was observed when mice were treated with intratumorally administered IMSA101 in addition to intravenous CAR T infusion.

In this webinar, Dr. Uslu describes how IMSA101 enhances CAR T function through STING agonist-induced IL-18 secretion and how these findings lay the foundation for advancing the combinatorial approach into a clinical setting.

This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. View the rest of the talks and read the Q&A transcripts.